Image source: Shutterstock

Highlights

  • Anne Whitaker brings 30+ years of experience in pharmaceuticals and biotech
  • Whitaker has held leadership roles at GlaxoSmithKline, Sanofi, and Bausch Health
  • Her expertise includes commercial risk management and M&A strategy in life sciences

Telix Pharmaceuticals (ASX/NASDAQ: TLX) has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. Whitaker's appointment brings a wealth of knowledge and experience to the company, stemming from over three decades in the pharmaceutical, biotech, and specialty pharmaceutical sectors.

Whitaker’s background includes a significant track record in clinical research, manufacturing, and corporate governance. She has served in senior roles at renowned companies such as GlaxoSmithKline, Sanofi, and Bausch Health. Additionally, Whitaker has extensive experience as a Non-Executive Director, having worked with prominent organizations like Icon PLC (NASDAQ: ICLR) and QurAlis, where she currently holds the position of Chair.

Her most recent executive role was as Chair and CEO of Aerami Therapeutics Holdings, where she led strategic growth initiatives. Her appointment at Telix Pharmaceuticals underscores her capability in steering companies through complex commercial and risk management challenges, particularly in mergers and acquisitions (M&A).

Whitaker holds a Bachelor of Science in Chemistry and Business from the University of North Alabama, reinforcing her strong technical and business foundation. This combination of leadership and industry knowledge positions her as a valuable addition to Telix's board, especially in enhancing its strategic direction and global market presence.

As Telix Pharmaceuticals continues its growth trajectory in the life sciences sector, Whitaker's insights into governance, corporate strategy, and market expansion will likely play a crucial role in its ongoing efforts to build value for stakeholders.